SHARE BASED COMPENSATION (Details Narrative) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands |
1 Months Ended | 12 Months Ended | ||||
|---|---|---|---|---|---|---|
Mar. 31, 2022 |
Jul. 17, 2015 |
Dec. 31, 2025 |
Dec. 31, 2024 |
Dec. 31, 2023 |
Dec. 31, 2022 |
|
| Statement [Line Items] | ||||||
| Fair value per share | $ 2.06 | |||||
| Proceeds from issuance of stock | $ 0 | $ 0 | $ 1,150 | |||
| General And Administrative Expenses [member] | ||||||
| Statement [Line Items] | ||||||
| Back pay settled through equity instruments | 136,250 | |||||
| Research And Development Expenses [member] | ||||||
| Statement [Line Items] | ||||||
| Back pay settled through equity instruments | 136,250 | |||||
| Dr Averback [member] | ||||||
| Statement [Line Items] | ||||||
| Total restricted shares granted | 21,000,000 | |||||
| Monthly restricted shares granted | 250,000 | |||||
| Fair value per share | $ 1.36 | |||||
| Compensation expense | $ 86,749 | |||||
| Proceeds from issuance of stock | $ 6,400,000 | |||||
| Share-based payment expense | $ 272,500 | $ 272,500 | ||||
| Back pay settled through equity instruments | 3,000 | |||||
| Restricted shares granted | 3,000,000 | |||||